NEURACAP
Sector ReportSep 28, 2026 · 20 pages · Free to read

Vaccines Sector Outlook — September 2026

NeuraCap's Vaccines sector outlook: who plays, how the market prices them, what has transacted, and what it means for owners, operators and acquirers.

Download PDFDownload PowerPoint

Key figures

10.7x
Sector median EV/Revenue
57.7x
Premium end EV/Revenue vs 2.2x at the discount end
7
Transactions with disclosed terms

Read the report

C:\Users\dawoo\OneDrive\Desktop\Deployments\neuracap_sector_reports_fable\Code\NeuraCap_Sector_Report_Pipeline_v2.1.0\ncsr\deck_kit\assets\logo_light_full.png

HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › VACCINES

Vaccines: Price Attaches to Programme Promise

How the vaccine peer set and the recent transaction record value platform evidence, schedule position and dose supply.

September 2026 · Prepared by NeuraCap AI · Confidential

Market data as of 2026-09-28 · primary valuation basis EV / Revenue (CY2027E)

Vaccines Coverage | September 2026 | Confidential | Not investment advice

1

1 / 20

Executive summary

Vaccines sits under one label as two businesses: eleven clinical-stage platform developers valued on programme evidence, and one contract drug substance and fill-finish supplier valued on capacity and contracts. On a forward revenue lens the distance between the top and the bottom of the range is wide, and the higher multiples sit with the faster-growing names rather than with the larger revenue bases.

Key findings

  • The Top of the Range and the Bottom Are Not the Same Business
  • Faster Forward Growth Sits Alongside the Higher Multiples
  • Pipeline Names and the Supply Name Are Priced on Different Standards
  • Whole-Company Values Agreed in the Record Sit Below Where the Set Trades

What each page shows

The analyst’s walkthrough of the deck, page by page.

  1. 01

    HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › VACCINES

    HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › VACCINES.

    Cover — Vaccines sector insights, September 2026. Prepared by NeuraCap AI; market data as of 2026-09-28; primary valuation basis EV / Revenue (CY2027E). The framing line carries the deck's finding with the figures stripped. 1

    Everything on this page

    HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › VACCINES Vaccines: Price Attaches to Programme Promise How the vaccine peer set and the recent transaction record value platform evidence, schedule position and dose supply. September 2026 · Prepared by NeuraCap AI · Confidential Market data as of 2026-09-28 · primary valuation basis EV / Revenue (CY2027E) Vaccines Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 1

  2. 02
    CONTENTS

    What This Report Covers

    What This Report Covers.

    Contents — the report runs 5 numbered sections plus the appendix: the bottom line, the landscape, valuation & situations, precedent transactions, strategic implications. The Bottom Line comes first by design: a reader who stops after section 01 still leaves with the whole story. 2

    Everything on this page

    CONTENTS What This Report Covers 01 The Bottom Line Two Businesses Sit Under the Vaccines Label, and They Are Priced Differently 02 The Landscape Most of the Set Sits in Clinical-Stage Platforms; One Name Holds the Supply Side 03 Valuation & Situations The Range Is Wide, and Only Two Names Sit at the Top of It 04 Precedent Transactions Buyers Agreed Whole-Company Values Well Below Where the Set Trades 05 Strategic Implications The Operating Moves That Sit with the Higher End of the Range 06 Appendix Comparables Detail, Methodology, Sources and Assumptions Vaccines Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 2

  3. 03
    01 · THE BOTTOM LINE

    The Vaccine Sector Splits into Two Businesses: Clinical-Stage Platform Developers and Contract Fill-Finish Supply

    The Vaccine Sector Splits into Two Businesses: Clinical-Stage Platform Developers and Contract Fill-Finish Supply.

    The Vaccine Sector Splits into Two Businesses: Clinical-Stage Platform Developers and Contract Fill-Finish Supply The full story on one page · figures on EV / Revenue (CY2027E), market data as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: EV / Revenue on CY2027E consensus (9 of 12 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Qualitative characterisations are NeuraCap views. 3

    Everything on this page

    01 · THE BOTTOM LINE The Vaccine Sector Splits into Two Businesses: Clinical-Stage Platform Developers and Contract Fill-Finish Supply The full story on one page · figures on EV / Revenue (CY2027E), market data as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: EV / Revenue on CY2027E consensus (9 of 12 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Qualitative characterisations are NeuraCap views. Vaccines Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 3 1 The Top of the Range and the Bottom Are Not the Same Business Across the nine names with a forward estimate, the top of the range prices at 57.7x forward revenue and the bottom at 2.2x. Revenue is the lens here because forward profit figures are reported too thinly across this set to carry the comparison, and a forward multiple already credits forecast growth, so a premium that survives it points to durability. 2 Faster Forward Growth Sits Alongside the Higher Multiples The four names growing above 14% sit at 20.9x in the middle of that group, against 4.1x for the three below that mark. That rests on the seven names carrying a forward growth estimate, a small base, and it is an association rather than a rule. 3 Pipeline Names and the Supply Name Are Priced on Different Standards Eleven of the twelve names in the set are clinical-stage vaccine platform developers, 92% of the set, and they are valued on programme evidence: immunogenicity readouts, serotype coverage and a path to schedule placement. Emergent BioSolutions Inc. (EBS), the one contract drug substance and fill-finish name, prices at 1.1x, where capacity utilisation and cost per dose sit underneath the number. 4 Whole-Company Values Agreed in the Record Sit Below Where the Set Trades Three of the seven transactions in this record disclose a revenue multiple on a vaccine target: 3.5x, 1.6x and 1.5x. Sanofi, AstraZeneca Pharmaceuticals LP and BioNTech SE are the buyers behind them, so these are strategic marks agreed by primes and platform owners, not financial ones. 10.7x Sector median EV/Revenue CY2027E consensus · EV/Revenue is the lens because only 0 of 12 names carry a meaningful forward EBITDA 57.7x Premium end EV/Revenue vs 2.2x at the discount end top quartile (n=2) against bottom quartile (n=3) on EV/Revenue — the spread the report explains 7 Transactions with disclosed terms 18 recorded in this tier · 3 told as case studies, the full list in the appendix

  4. 04
    SECTION 02

    02

    02.

    Section 02 of 06 — Most of the Set Sits in Clinical-Stage Platforms; One Name Holds the Supply Side. Where the twelve names in the set fall across two segments. Use this divider to reset the room before the section's pages; the progress dots show where the argument stands. 4

    Everything on this page

    SECTION 02 02 THE LANDSCAPE Most of the Set Sits in Clinical-Stage Platforms; One Name Holds the Supply Side Where the twelve names in the set fall across two segments. 02 of 06 Vaccines Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 4

  5. 05
    02 · MARKET MAP

    Where the Vaccine Money Sits: Programme Pipelines on One Side, Dose Supply on the Other

    Where the Vaccine Money Sits: Programme Pipelines on One Side, Dose Supply on the Other.

    Where the Vaccine Money Sits: Programme Pipelines on One Side, Dose Supply on the Other 12 approved companies grouped by business segment · median EV / Revenue (CY2027E) per group · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Segment grouping follows the platform's classification; group medians on rated names only. "Why it matters" lines are NeuraCap views. 5

    Everything on this page

    02 · MARKET MAP Where the Vaccine Money Sits: Programme Pipelines on One Side, Dose Supply on the Other 12 approved companies grouped by business segment · median EV / Revenue (CY2027E) per group · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Segment grouping follows the platform's classification; group medians on rated names only. "Why it matters" lines are NeuraCap views. Vaccines Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 5 CLINICAL-STAGE VACCINE PLATFORM DEVELOPERS 11 cos median 20.3x Moderna (MRNA) BioNTech SE (BNTX) Vaxcyte (PCVX) SELLAS Life (SLS) Novavax (NVAX) Valneva SE (VALN) Greenwich (GLSI) Arcturus (ARCT) Inovio (INO) Elicio (ELTX) Vaxart (VXRT) Eleven of the twelve names sit here, and value is built programme by programme — immunogenicity, schedule placement and the cohorts that follow. VACCINE DRUG SUBSTANCE AND FILL-FINISH MANUFACTURE (CONTRACT SUPPLY) 1 cos 1.1x · 1 rated Emergent (EBS) One name carries the supply side, where capacity utilisation, cost per dose and government option-exercise cycles are the operating measures.

  6. 06
    02 · LANDSCAPE

    One Sector Label Covers a Pipeline Business and a Supply Business

    One Sector Label Covers a Pipeline Business and a Supply Business.

    One Sector Label Covers a Pipeline Business and a Supply Business Segment view of the approved universe · EV / Revenue (CY2027E) medians on rated names · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. "What they do / why it matters" is a NeuraCap view. Full company-level detail in the appendix and companion tables. 6

    Everything on this page

    02 · LANDSCAPE One Sector Label Covers a Pipeline Business and a Supply Business Segment view of the approved universe · EV / Revenue (CY2027E) medians on rated names · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. "What they do / why it matters" is a NeuraCap view. Full company-level detail in the appendix and companion tables. Vaccines Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 6 Segment n Share of universe Median EV/Revenue Names to know What they do — and why it matters Clinical-stage vaccine platform developers 11 92% 20.3x Moderna, Inc. (MRNA) · BioNTech SE (BNTX) · +9 more Priced on pipeline evidence. Eleven names, 92% of the set, develop prophylactic and therapeutic vaccines across delivery routes, adjuvant systems and conjugation chemistry. Eight of them carry a forward estimate and the median of that group sits at 20.3x, so a buyer of these stories is underwriting immunogenicity data, serotype coverage and a credible path to schedule placement. Vaccine drug substance and fill-finish manufacture (contract supply) 1 8% 1.1x n=1 Emergent BioSolutions Inc. (EBS) Capacity, contracts and cost. Emergent BioSolutions Inc. (EBS) is the single name here, at 1.1x forward revenue, with drug substance and fill-finish work and countermeasure supply underneath it. Revenue follows appropriations, option years and stockpile replenishment rather than end-market demand, and the multiple sits well below the pipeline names.

  7. 07
    SECTION 03

    03

    03.

    Section 03 of 06 — The Range Is Wide, and Only Two Names Sit at the Top of It. Forward revenue multiples across the twelve names in the set, nine of them with a forward estimate. Use this divider to reset the room before the section's pages; the progress dots show where the argument stands. 7

    Everything on this page

    SECTION 03 03 VALUATION & SITUATIONS The Range Is Wide, and Only Two Names Sit at the Top of It Forward revenue multiples across the twelve names in the set, nine of them with a forward estimate. 03 of 06 Vaccines Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 7

  8. 08
    03 · PUBLIC MARKET VALUATION

    The Top of the Range Sits with Programme Promise, the Bottom with Doses Already Shipped

    The Top of the Range Sits with Programme Promise, the Bottom with Doses Already Shipped.

    The Top of the Range Sits with Programme Promise, the Bottom with Doses Already Shipped EV / Revenue (CY2027E) · all 9 rated companies, sorted descending · sector median 10.7x · EV/Revenue is the lens because only 0 of 12 names carry a meaningful forward EBITDA · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: EV / Revenue on CY2027E consensus (9 of 12 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Tier zones are NeuraCap groupings cut at the rated set's quartiles; every multiple quoted on this page is a median on the same EV / Revenue (CY2027E) basis. Panel commentary is a NeuraCap view. 8

    Everything on this page

    03 · PUBLIC MARKET VALUATION The Top of the Range Sits with Programme Promise, the Bottom with Doses Already Shipped EV / Revenue (CY2027E) · all 9 rated companies, sorted descending · sector median 10.7x · EV/Revenue is the lens because only 0 of 12 names carry a meaningful forward EBITDA · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: EV / Revenue on CY2027E consensus (9 of 12 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Tier zones are NeuraCap groupings cut at the rated set's quartiles; every multiple quoted on this page is a median on the same EV / Revenue (CY2027E) basis. Panel commentary is a NeuraCap view. Vaccines Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 8 PREMIUM · median 57.7x CORE · median 20.3x DISCOUNT · median 2.2x Sector median 10.7x WHAT SEPARATES THE TWO ENDS The top prices on pipelines. Vaxcyte, Inc. (PCVX) and SELLAS Life Sciences Group, Inc. (SLS) mark the top of the range at 57.7x forward revenue, with programmes still ahead of commercial scale. A forward multiple already credits forecast revenue, so a mark that high rests on what those programmes are expected to become. The bottom carries shipped doses. BioNTech SE (BNTX), Valneva SE (VALN) and Emergent BioSolutions Inc. (EBS) sit at 2.2x in the middle of that group, with revenue already on the books and demand normalising out of the pandemic years into an endemic, tender-driven market. Four names sit in between. Moderna, Inc. (MRNA), Greenwich LifeSciences, Inc. (GLSI), Arcturus Therapeutics Holdings Inc. (ARCT) and Novavax, Inc. (NVAX) fall between the two ends. For an owner, the practical question is which side of that line the next readout or schedule decision moves a company toward.

  9. 09
    03 · VALUATION DRIVERS

    Faster Forward Growth Sits with the Higher Multiples in This Set

    Faster Forward Growth Sits with the Higher Multiples in This Set.

    Faster Forward Growth Sits with the Higher Multiples in This Set Median EV / Revenue (CY2027E) by revenue-growth cohort and by EBITDA-margin cohort (each split at its covered median) · rated names with estimates · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Cohort medians on rated names with the required estimates (faster n=4; slower n=3; higher-margin n=0; lower-margin n=0). Driver readings are NeuraCap views on the supplied data — association, not causation. 9

    Everything on this page

    03 · VALUATION DRIVERS Faster Forward Growth Sits with the Higher Multiples in This Set Median EV / Revenue (CY2027E) by revenue-growth cohort and by EBITDA-margin cohort (each split at its covered median) · rated names with estimates · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Cohort medians on rated names with the required estimates (faster n=4; slower n=3; higher-margin n=0; lower-margin n=0). Driver readings are NeuraCap views on the supplied data — association, not causation. Vaccines Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 9 EV/Revenue, median per cohort · growth split at 14% · EBITDA-margin split at n/a Above 14% Forward Growth Sits at 20.9x; Below That Mark, 4.1x On the seven names carrying a forward growth estimate, the four growing above 14% have a median forward revenue multiple of 20.9x against 4.1x for the three below. Seven names is a small base, so read the gap as an association between growth and price, not as a mechanism. There Is No Usable Profit Line to Test the Split Against Forward EBITDA is not meaningful across this set, so the profit multiple that frames manufacturing and countermeasure supply elsewhere cannot be run here. That leaves revenue quality — contracted doses against doses shipped, schedule placement and public-channel position — as the evidence that carries a multiple. Concentration and Appropriation Timing Show up at the Lower End The lower end of the range holds names whose revenue is tied to a lone pathogen, a lone customer, or government option years. Valneva SE (VALN) carries 91% forward growth and still sits at the bottom of the range, which is a reminder that a growth number alone is not what the market is reading. A Declining Forward Line Does Not Settle Where a Name Sits Novavax, Inc. (NVAX) carries -26% forward growth and prices at 4.8x, while BioNTech SE (BNTX), at -1%, sits in the lower group. Where a name lands appears to track the evidence behind its next programme as much as the direction of this year's revenue.

  10. 10
    03 · SITUATION MAP

    Where the Money Sits in Vaccines: With Profit Lines Limited, Revenue Multiples Carry the Valuation

    Where the Money Sits in Vaccines: With Profit Lines Limited, Revenue Multiples Carry the Valuation.

    Where the Money Sits in Vaccines: With Profit Lines Limited, Revenue Multiples Carry the Valuation Cut on EV / Revenue vs the sector median (10.7x) (rows) and EBITDA margin vs the covered median (n/a) (columns) · 9 rated names without the second measure are not mapped · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Situation boundaries are the cohort's own medians (Directional, NeuraCap view). This page characterises situations; it does not recommend buying or selling any security. 10

    Everything on this page

    03 · SITUATION MAP Where the Money Sits in Vaccines: With Profit Lines Limited, Revenue Multiples Carry the Valuation Cut on EV / Revenue vs the sector median (10.7x) (rows) and EBITDA margin vs the covered median (n/a) (columns) · 9 rated names without the second measure are not mapped · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Situation boundaries are the cohort's own medians (Directional, NeuraCap view). This page characterises situations; it does not recommend buying or selling any security. Vaccines Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 10 Priced up and Earning Now Above-median multiple · above-median EBITDA margin 0 names No rated names sit in this cell as of the analysis date. Priced up, Profit Still Ahead Above-median multiple · below-median EBITDA margin 0 names No rated names sit in this cell as of the analysis date. Earning Now, Priced Below the Middle Below-median multiple · above-median EBITDA margin 0 names No rated names sit in this cell as of the analysis date. Below the Middle on Both Below-median multiple · below-median EBITDA margin 0 names No rated names sit in this cell as of the analysis date.

  11. 11
    03 · THE AGENDA

    The Two Ends of the Vaccine Range Reflect Two Different Operating Models

    The Two Ends of the Vaccine Range Reflect Two Different Operating Models.

    The Two Ends of the Vaccine Range Reflect Two Different Operating Models NeuraCap view · framed as the questions an owner or acquirer should resolve · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All content on this page is Directional — NeuraCap advisory judgment grounded in the cohort data shown earlier. It does not constitute investment advice. 11

    Everything on this page

    03 · THE AGENDA The Two Ends of the Vaccine Range Reflect Two Different Operating Models NeuraCap view · framed as the questions an owner or acquirer should resolve · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All content on this page is Directional — NeuraCap advisory judgment grounded in the cohort data shown earlier. It does not constitute investment advice. Vaccines Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 11 Build the Evidence That Sits with the Top of the Range The top of this peer set is held by names whose value rests on programme evidence rather than on shipped revenue. The operating work is immunogenicity and seroconversion data strong enough to support schedule placement, and serotype or strain coverage that stands against the incumbent standard of care. What changes the answer: A pivotal immunogenicity readout, or an advisory committee decision on schedule placement. Decide Whether Owned Manufacturing Is an Asset or an Overhead In-house drug substance and fill-finish control reduces supply dependence, and it carries utilisation risk when demand normalises. The contract supply name in this set is priced on capacity economics, which is the standard a plant-owning developer will be measured against. What changes the answer: Utilisation falling below the level at which reservation and take-or-pay commitments still pay for themselves. Reduce Dependence on a Lone Pathogen or a Lone Customer Revenue concentrated in one pathogen, or in appropriations and option years, sits at the lower end of this range. Broadening into co-administration and combination positions, pediatric cohorts and prequalified multilateral tenders changes the shape of revenue, not only its size. What changes the answer: A stockpile option year left unexercised, or a pooled tender lost on prequalification grounds. Choose Build-Versus-Buy on Delivery and Adjuvant Technology The recent transaction record shows primes and platform owners agreeing whole-company values for technology and pipeline position. For an owner, the question is whether the delivery route, adjuvant system or conjugation know-how is faster to build in-house or to acquire. What changes the answer: A licensing or tech-transfer term sheet that prices the same capability below the cost of the internal programme.

  12. 12
    SECTION 04

    04

    04.

    Section 04 of 06 — Buyers Agreed Whole-Company Values Well Below Where the Set Trades. Seven transactions in the record; four carry a disclosed revenue multiple. Use this divider to reset the room before the section's pages; the progress dots show where the argument stands. 12

    Everything on this page

    SECTION 04 04 PRECEDENT TRANSACTIONS Buyers Agreed Whole-Company Values Well Below Where the Set Trades Seven transactions in the record; four carry a disclosed revenue multiple. 04 of 06 Vaccines Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 12

  13. 13
    04 · DEAL CASE STUDIES

    Vaccine Transactions Are Priced at Both Ends: Platform Assets and Fill-Finish Supply

    Vaccine Transactions Are Priced at Both Ends: Platform Assets and Fill-Finish Supply.

    Vaccine Transactions Are Priced at Both Ends: Platform Assets and Fill-Finish Supply 3 of 7 transactions with disclosed terms, told as case studies · multiples on LTM financials at announcement where disclosed · the complete list is in the appendix · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 29 precedent record(s) carry data-quality flags (deal value unit unresolved; duplicate precedent id; no evidence record); figures are shown as recorded in the filing. 11 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed.

    Everything on this page

    04 · DEAL CASE STUDIES Vaccine Transactions Are Priced at Both Ends: Platform Assets and Fill-Finish Supply 3 of 7 transactions with disclosed terms, told as case studies · multiples on LTM financials at announcement where disclosed · the complete list is in the appendix · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 29 precedent record(s) carry data-quality flags (deal value unit unresolved; duplicate precedent id; no evidence record); figures are shown as recorded in the filing. 11 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. "Why the deal happened" is a NeuraCap read of the recorded evidence. Vaccines Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 13 Dec-2025 $2.3B Sanofi acquires Dynavax Technologies Corporation EV / LTM revenue 3.5x EV / LTM EBITDA n/a WHY THE DEAL HAPPENED Sanofi sits in the concentrated group of global vaccine primes, and Dynavax Technologies Corporation is a vaccine developer with disclosed revenue behind its multiple. A prime buyer alongside a revenue-generating vaccine target suggests a transaction about recommendation-anchored demand and platform and manufacturing fit. HOW THE TARGET WAS VALUED The transaction is recorded at $2.3B and 3.5x revenue, completed in Dec-2025. That mark sits below the middle of the range for the nine names with a forward estimate, the usual pattern when whole companies change hands against a forward trading lens. Oct-2025 $1.6B AstraZeneca Pharmaceuticals LP acquires Novavax, Inc. EV / LTM revenue 1.5x EV / LTM EBITDA n/a WHY THE DEAL HAPPENED AstraZeneca Pharmaceuticals LP is a diversified pharmaceutical acquirer and Novavax, Inc. (NVAX) is a clinical-stage vaccine platform developer with product revenue. A buyer of that type alongside a platform developer of this size suggests the transaction is about platform technology and supply position rather than a single product line. HOW THE TARGET WAS VALUED The deal is recorded at $1.6B and 1.5x revenue, announced in Oct-2025 and not shown as completed. It benchmarks below the middle of the range for the nine names with a forward estimate, consistent with the other whole-company marks in this record. Jun-2025 $849M BioNTech SE acquires CureVac N.V. EV / LTM revenue 1.6x EV / LTM EBITDA n/a WHY THE DEAL HAPPENED BioNTech SE (BNTX) sits in this peer set as a clinical-stage vaccine platform developer, and CureVac N.V. operates in the same segment. A buyer and target inside one segment, at this size, suggests a transaction about delivery technology, intellectual property position and pipeline consolidation rather than about acquiring sales. HOW THE TARGET WAS VALUED The transaction is recorded at $849M and 1.6x revenue, announced in Jun-2025. It is a single-digit revenue mark against a peer set whose middle sits far higher on the forward lens, a gap that is typical between agreed whole-company values and forward trading multiples.

  14. 14
    SECTION 05

    05

    05.

    Section 05 of 06 — The Operating Moves That Sit with the Higher End of the Range. What the peer set and the transaction record mean for owners, boards and capital allocation. Use this divider to reset the room before the section's pages; the progress dots show where the argument stands. 14

    Everything on this page

    SECTION 05 05 STRATEGIC IMPLICATIONS The Operating Moves That Sit with the Higher End of the Range What the peer set and the transaction record mean for owners, boards and capital allocation. 05 of 06 Vaccines Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 14

  15. 15
    05 · STRATEGIC IMPLICATIONS

    Vaccine Platform Developers Hold the Top of the Range, While Fill-Finish Supply Names Sit at the Bottom

    Vaccine Platform Developers Hold the Top of the Range, While Fill-Finish Supply Names Sit at the Bottom.

    Vaccine Platform Developers Hold the Top of the Range, While Fill-Finish Supply Names Sit at the Bottom NeuraCap view · the questions this data puts on the table for the next twelve months Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. This page is Directional — NeuraCap views drawn from the analysis in this report. Observations, not recommendations. 15

    Everything on this page

    05 · STRATEGIC IMPLICATIONS Vaccine Platform Developers Hold the Top of the Range, While Fill-Finish Supply Names Sit at the Bottom NeuraCap view · the questions this data puts on the table for the next twelve months Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. This page is Directional — NeuraCap views drawn from the analysis in this report. Observations, not recommendations. Vaccines Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 15 FOR OWNERS Revenue Quality Is the Lever You Hold This set prices programme promise well above revenue already shipped, while the values buyers agreed for whole companies are single-digit revenue marks. Contracted doses, schedule placement and public-channel position are what make revenue durable enough to close that gap. FOR BOARDS Test the Concentration Inside the Revenue You Already Have A lone pathogen, a lone customer or appropriation-driven order timing shows up at the lower end of this range. Ask what share of forward revenue depends on an option year being exercised, and what the operating plan is if it is not. FOR CAPITAL ALLOCATION Fund the Programme That Reaches Its Readout Buyers in this record committed around data, and option-to-acquire structures let a prime pay for evidence rather than for expectation. Funding one programme to its pivotal immunogenicity or efficacy readout is the allocation decision that changes what the market and a buyer can underwrite.

  16. 16
    SECTION 06

    06

    06.

    Section 06 of 06 — The Full Universe, Methodology and Sources. Comparables detail behind every figure in the body, the valuation basis, and where each underlying disclosure lives. Use this divider to reset the room before the section's pages; the progress dots show where the argument stands. 16

    Everything on this page

    SECTION 06 06 APPENDIX The Full Universe, Methodology and Sources Comparables detail behind every figure in the body, the valuation basis, and where each underlying disclosure lives. 06 of 06 Vaccines Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 16

  17. 17
    06 · PUBLIC COMPARABLES (1 OF 1)

    Public Comparables on EV / Revenue (CY2027E), Grouped by Valuation Tier

    Public Comparables on EV / Revenue (CY2027E), Grouped by Valuation Tier.

    Public Comparables on EV / Revenue (CY2027E), Grouped by Valuation Tier Teal shading marks a EV/Revenue above the sector median (10.7x); amber marks below · 9 rated companies; 3 not rated (no eligible EV/Revenue) · tickers link to the underlying source · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All 9 rated rows are in this appendix and in the companion workbook, which carries the complete field set. Names without an eligible multiple are listed in the companion workbook. 17

    Everything on this page

    06 · PUBLIC COMPARABLES (1 OF 1) Public Comparables on EV / Revenue (CY2027E), Grouped by Valuation Tier Teal shading marks a EV/Revenue above the sector median (10.7x); amber marks below · 9 rated companies; 3 not rated (no eligible EV/Revenue) · tickers link to the underlying source · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All 9 rated rows are in this appendix and in the companion workbook, which carries the complete field set. Names without an eligible multiple are listed in the companion workbook. Vaccines Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 17 Company Ticker Segment EV EV/Revenue (CY2027E) Rev growth EBITDA margin Rule of 40 PREMIUM — ≥31.1x · median 57.7x · 2 companies Vaxcyte, Inc. PCVX Clinical-stage vaccine platform developers $6.8B 77.9x n/a n/a n/a SELLAS Life Sciences Group, Inc. SLS Clinical-stage vaccine platform developers $2.0B 37.6x 47% n/a n/a CORE — 4.1x–31.1x · median 20.3x · 4 companies Moderna, Inc. MRNA Clinical-stage vaccine platform developers $74.4B 31.1x 14% n/a n/a Greenwich LifeSciences, Inc. GLSI Clinical-stage vaccine platform developers $262M 30.0x n/a n/a n/a Arcturus Therapeutics Holdings Inc. ARCT Clinical-stage vaccine platform developers $219M 10.7x 15% n/a n/a Novavax, Inc. NVAX Clinical-stage vaccine platform developers $1.3B 4.8x -26% n/a n/a DISCOUNT — <4.1x · median 2.2x · 3 companies BioNTech SE BNTX Clinical-stage vaccine platform developers $8.3B 4.1x -1% n/a n/a Valneva SE VALN Clinical-stage vaccine platform developers $734M 2.2x 91% n/a n/a Emergent BioSolutions Inc. EBS Vaccine drug substance and fill-finish manufacture… $780M 1.1x 7% n/a n/a

  18. 18
    06 · PRECEDENT TRANSACTIONS (1 OF 1)

    All Precedent Transactions with Disclosed Terms, Newest First

    All Precedent Transactions with Disclosed Terms, Newest First.

    All Precedent Transactions with Disclosed Terms, Newest First 7 transactions with disclosed terms in this tier (18 recorded) · multiples on LTM financials at announcement where disclosed · deal values link to the underlying filing · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 29 precedent record(s) carry data-quality flags (deal value unit unresolved; duplicate precedent id; no evidence record); figures are shown as recorded in the filing. 11 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. 18

    Everything on this page

    06 · PRECEDENT TRANSACTIONS (1 OF 1) All Precedent Transactions with Disclosed Terms, Newest First 7 transactions with disclosed terms in this tier (18 recorded) · multiples on LTM financials at announcement where disclosed · deal values link to the underlying filing · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 29 precedent record(s) carry data-quality flags (deal value unit unresolved; duplicate precedent id; no evidence record); figures are shown as recorded in the filing. 11 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. Vaccines Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 18 Date Transaction EV EV/LTM Rev EV/LTM EBITDA Why it matters Dec-2025 Sanofi → Dynavax Technologies Corporation $2.3B 3.5x n/a Completed in Dec-2025 at $2.3B, this is a global vaccine prime acquiring a vaccine developer with disclosed revenue behind the multiple. For an owner, it marks the size a prime will commit when product revenue is already in place. Oct-2025 AstraZeneca Pharmaceuticals LP → Novavax, Inc. $1.6B 1.5x n/a Announced in Oct-2025 at $1.6B, AstraZeneca Pharmaceuticals LP agreed to acquire Novavax, Inc. (NVAX), which also sits in this peer set at 4.8x forward revenue. The transaction is announced rather than completed, so read it as a value agreed, not a payment made. Aug-2025 XOMA Royalty Corporation → HilleVax, Inc. $68M n/a n/a XOMA Royalty Corporation agreed $68M for HilleVax, Inc. in Aug-2025, recorded as completed. Royalty and structured buyers remain an active route for earlier-stage vaccine assets at a point where a prime would typically wait for pivotal data. Jun-2025 BioNTech SE → CureVac N.V. $849M 1.6x n/a BioNTech SE (BNTX) agreed $849M for CureVac N.V. in Jun-2025, announced. A buyer and target in the same segment at this size points at delivery technology and intellectual property position as the substance of the transaction. Apr-2024 Kintara Therapeutics, Inc. → TuHURA Biosciences, Inc. $5M n/a n/a Kintara Therapeutics, Inc. is recorded at $5M for TuHURA Biosciences, Inc. in Apr-2024, completed. At that size the transaction reads as a corporate combination, a live route for earlier-stage developers to reach public markets. Dec-2023 AstraZeneca PLC → Icosavax, Inc. $745M n/a n/a AstraZeneca PLC announced $745M for Icosavax, Inc. in Dec-2023, with no revenue multiple recorded. A whole-company value at that level without a revenue mark attached is the shape of a programme purchase, priced on data rather than on sales. Nov-2015 Zoetis Inc. → PHARMAQ Holding AS n/a 8.8x 0.7x Zoetis Inc.'s Nov-2015 purchase of PHARMAQ Holding AS is recorded at 8.8x revenue and 0.7x EBITDA, with deal value recorded as n/a. It is the oldest entry here and sits outside human vaccine supply, so weight it lightly against the recent marks.

  19. 19
    06 · METHODOLOGY

    Sources, Assumptions and Data Quality

    Sources, Assumptions and Data Quality.

    Sources, Assumptions and Data Quality How this report was built, what was excluded, and where every underlying disclosure lives · as of 2026-09-28 Every figure in this report links to the record it was taken from. Where a figure has no link, the appendix names its source and the basis on which it was read. 19

    Everything on this page

    06 · METHODOLOGY Sources, Assumptions and Data Quality How this report was built, what was excluded, and where every underlying disclosure lives · as of 2026-09-28 Every figure in this report links to the record it was taken from. Where a figure has no link, the appendix names its source and the basis on which it was read. Vaccines Coverage | September 2026 | Confidential | Not investment advice 19 VALUATION BASIS Primary valuation basis: EV / Revenue on CY2027E consensus (9 of 12 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). EV / Revenue on CY2027E is the lead convention: it is the sector-appropriate prior for Vaccines and it clears the coverage gate with 11 of 12 companies (92%). No secondary cross-check clears its own gate. A revenue lens is used rather than a profit multiple because 5 of the 5 companies with a reported forward EBITDA carry no meaningful one, so a profit multiple cannot describe this set. DATA QUALITY & EXCLUSIONS 55 records were excluded or quarantined by the platform's validation gates (unit errors, implausible ratios, ineligible securities and classification failures); the full ledger ships in the companion tables and never feeds a statistic in this report. DEFINITIVE VS DIRECTIONAL Definitive content is disclosed or consensus data passed through stated arithmetic. Directional content — tier boundaries, situation cuts, "why it matters" commentary, the agenda pages — is NeuraCap analyst judgment and is labeled as such where it appears. WHAT THIS REPORT IS NOT This report characterises a sector. It does not recommend buying, selling or holding any security, and no statement in it should be read as investment advice or a price target. WHERE THE DATA LIVES 363 registered source documents stand behind the figures in this report. Metric hyperlinks throughout the deck open the specific filing or data record; by publisher: sec.gov (362) · home.treasury.gov (1). The companion workbook beside this deck carries the complete source index.

  20. 20

    In Vaccines, the Top of the Range Sits with Evidence; The Bottom, with Doses Already Shipped.

    In Vaccines, the Top of the Range Sits with Evidence; The Bottom, with Doses Already Shipped..

    Closing — In Vaccines, the Top of the Range Sits with Evidence; The Bottom, with Doses Already Shipped. The companion tables beside this deck carry the full universe, the exclusion ledger and the complete source index for any figure a client wants to trace. 20

    Everything on this page

    In Vaccines, the Top of the Range Sits with Evidence; The Bottom, with Doses Already Shipped. NeuraCap AI — Vaccines Coverage September 2026 · Prepared by NeuraCap AI · Confidential Vaccines Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 20

Sources and methodology

This report covers Vaccines (Health Care › Pharmaceuticals, Biotechnology and Life Sciences › Vaccines) with market data and consensus estimates as of September 28, 2026. The company universe is the 12 listed companies whose core business is Vaccines according to NeuraCap's industry classification of each company's reported business segments (a company is included only when this industry is central to what it does, not merely adjacent to it). Companies in the set: Arcturus Therapeutics Holdings Inc. (ARCT), BioNTech SE (BNTX), Emergent BioSolutions Inc. (EBS), Elicio Therapeutics, Inc. (ELTX), Greenwich LifeSciences, Inc. (GLSI), Inovio Pharmaceuticals, Inc. (INO), Moderna, Inc. (MRNA), Novavax, Inc. (NVAX), Vaxcyte, Inc. (PCVX), SELLAS Life Sciences Group, Inc. (SLS), Valneva SE (VALN), Vaxart, Inc. (VXRT). The market map groups them by business vertical — Clinical-stage vaccine platform developers: 11 companies (MRNA, BNTX, PCVX, SLS, NVAX, VALN, GLSI, ARCT, INO, ELTX, VXRT); Vaccine drug substance and fill-finish manufacture (contract supply): 1 company (EBS). 9 of the 12 companies carry a valid multiple on the primary valuation basis and form the rated set behind every cohort statistic; the others are shown but do not enter the statistics.

Scope and company universe

This report covers Vaccines (Health Care › Pharmaceuticals, Biotechnology and Life Sciences › Vaccines) with market data and consensus estimates as of September 28, 2026. The company universe is the 12 listed companies whose core business is Vaccines according to NeuraCap's industry classification of each company's reported business segments (a company is included only when this industry is central to what it does, not merely adjacent to it). Companies in the set: Arcturus Therapeutics Holdings Inc. (ARCT), BioNTech SE (BNTX), Emergent BioSolutions Inc. (EBS), Elicio Therapeutics, Inc. (ELTX), Greenwich LifeSciences, Inc. (GLSI), Inovio Pharmaceuticals, Inc. (INO), Moderna, Inc. (MRNA), Novavax, Inc. (NVAX), Vaxcyte, Inc. (PCVX), SELLAS Life Sciences Group, Inc. (SLS), Valneva SE (VALN), Vaxart, Inc. (VXRT). The market map groups them by business vertical — Clinical-stage vaccine platform developers: 11 companies (MRNA, BNTX, PCVX, SLS, NVAX, VALN, GLSI, ARCT, INO, ELTX, VXRT); Vaccine drug substance and fill-finish manufacture (contract supply): 1 company (EBS). 9 of the 12 companies carry a valid multiple on the primary valuation basis and form the rated set behind every cohort statistic; the others are shown but do not enter the statistics.

What was excluded and why

55 records failed a validation gate and never feed a statistic in this report (1 excluded from universe; 51 excluded from aggregate; 3 quarantined). Each exclusion, with its reason: ACIU — The ticker ACIU carries a preferred, warrant or unit suffix and the security name gives no sign of an operating company (effect: excluded from universe) · ARCT — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ARCT — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ARCT — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ARCT — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · BNTX — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · BNTX — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · BNTX — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · BNTX — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · BNTX — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ELTX — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · ELTX — Implied EBITDA margin -144.3% outside the plausible band [-100%, 80%] (effect: quarantined) · ELTX — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ELTX — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ELTX — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ELTX — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · GLSI — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · GLSI — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · GLSI — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · GLSI — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · INO — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · INO — Implied EBITDA margin -125425.9% outside the plausible band [-100%, 80%] (effect: quarantined) · INO — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · INO — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · INO — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · further items are listed in the companion tables.

Primary valuation basis and how it was chosen

Primary valuation basis: EV / Revenue on CY2027E consensus (9 of 12 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). EV / Revenue on CY2027E is the lead convention: it is the sector-appropriate prior for Vaccines and it clears the coverage gate with 11 of 12 companies (92%). No secondary cross-check clears its own gate. A revenue lens is used rather than a profit multiple because 5 of the 5 companies with a reported forward EBITDA carry no meaningful one, so a profit multiple cannot describe this set. The basis is selected in two steps: the industry's customary valuation conventions set the order of preference, and each convention is then tested for coverage — the share of companies with a valid, plausibility-checked multiple on the chosen period. A convention is used only when enough companies carry it; the best-covered convention is used, and disclosed, when none clears the threshold. Coverage measured for this report — EV / EBITDA: 0 of 12 companies; EV / rEVenue: 11 of 12 companies; P/E: 1 of 12 companies. 5 companies show a non-meaningful EV / EBITDA denominator and are excluded from that statistic. 9 companies show a non-meaningful P / E denominator and are excluded from that statistic.

How the multiples and statistics are computed

Enterprise value (EV) is market capitalisation at the as-of date plus total debt minus cash and equivalents from the latest reported balance sheet, reconciled against the platform's stored value and disclosed where the two differ. Forward multiples divide EV (or the share price for P/E) by the consensus estimate for the stated calendar period; trailing multiples use the last twelve months of reported figures from SEC filings. A multiple with a negative or immaterial denominator is treated as not meaningful and excluded from every statistic. Cohort statistics are medians and quartiles over the rated set only; a group median with fewer than three observations is shown as the single company's figure and labelled as such. Valuation tiers cut the rated set at its quartiles (tiers cut at the rated set's quartiles: Premium ≥31.1x, Core 4.1x–31.1x, Discount <4.1x — NeuraCap groupings). Revenue growth compares consecutive calendar-year consensus revenue; EBITDA margin divides consensus EBITDA by consensus revenue for the same period. Figures shown in this report and the calculation behind each: 10.7x = median(ev_revenue CY2027E) (9 rated companies) · 57.7x = median(ev_revenue CY2027E) within Premium tier (n=2) · 20.3x = median(ev_revenue CY2027E) within Core tier (n=4) · 2.2x = median(ev_revenue CY2027E) within Discount tier (n=3) · 20.9x = median(ev_revenue CY2027E) | growth ≥ 14% (n=4) · 4.1x = median(ev_revenue CY2027E) | growth < 14% (n=3)

Precedent transactions: what is in the record and why

The precedent record holds the M&A transactions in Vaccines recorded from SEC filings (8-K announcements and the documents they reference), newest first, with each value and multiple linked to the exact passage in the filing that states it. 18 transactions were recorded for this industry; 7 are shown. 11 recorded transactions with neither a disclosed value nor a multiple are omitted because they say nothing about price; they remain in the companion workbook. Deal multiples are enterprise value over the target's last-twelve-month revenue or EBITDA at announcement, as disclosed; they are not restated to the public basis and no spread to the public multiples is claimed. Before a transaction reaches the record it passes a screen for mirrored or duplicate filings of the same deal, for divestitures where the filer is the seller rather than the buyer, for carve-outs recorded under the parent's name, and for values whose citation describes something other than the price paid (a debt raise, a termination fee); such records are corrected or excluded and the correction is noted. Data-quality notes on this record: 15 × deal value unit unresolved; 12 × no evidence record; 2 × duplicate precedent id. Case studies lead with the 3 richest stories — disclosed value, a readable multiple, newest first.

Sources

Company financials and transaction terms come from the companies' own SEC filings on EDGAR (10-K, 10-Q and 8-K documents), linked from each figure in the report. Forward figures are analyst consensus estimates for the calendar periods shown. Share prices and market capitalisations are market data as of September 28, 2026. Treasury yields are published by the U.S. Department of the Treasury. 367 source documents stand behind this report; by publisher domain: sec.gov, home.treasury.gov (1). Every figure on every page is traceable to one of these records; nothing in the report is derived from outside data.

Interpretation and important notice

Tier labels, situation maps, the agenda and the implications pages are NeuraCap analytical views drawn from the recorded evidence and are labelled as such. The report is informational: it is not investment advice, not a recommendation to buy or sell any security, not an opinion of value and not an offer of any kind. Readers should perform their own diligence before acting on anything described here.

This report is published for information only. It is not a recommendation to buy or sell any security, an offer or solicitation, an appraisal or a fairness opinion, and no fiduciary relationship is created by reading it. Multiples that fail NeuraCap’s plausibility gates are excluded and never plotted. See the full methodology and the disclaimer.

More coverage in Health Care

Want this analysis for a company in Vaccines?

Company valuation reports run the same method against a single business — public or private.

Get a free sample reportBrowse the research